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Abstract 
Aims 
Urinary Kidney Injury Molecule-1 (KIM-1) is a marker of tubular damage and associated with worse 
outcome in heart failure (HF). Plasma KIM-1 has not been described in HF. 
Methods and results 
In a renal mechanistic cohort of 120 chronic HF patients, we established the association between  
plasma KIM-1, renal invasive hemodynamic parameters (renal blood flow (131I-Hippuran clearance) 
and measured glomerular filtration rate (GFR; 125I-Iothalamate)), and urinary tubular damage markers. 
The association between plasma KIM-1, plasma creatinine, and clinical outcome was further explored 
in a cohort of 2033 acute HF patients. 
Median plasma KIM-1 was 171.5 pg/mL (122.8 – 325.7) in chronic (N=99) and 295.1 pg/mL (182.2-
484.2) in acute HF (N=1588). In chronic HF, plasma KIM-1 was associated with GFR (P < 0.001), 
creatinine and cystatin C. Plasma KIM-1 was associated with urinary NAG, but not with other urinary 
tubular damage markers. Log plasma KIM-1 predicted adverse clinical outcome after adjustment for 
age, gender, and GFR (Hazard Ratio (HR)=1.94 [1.07 – 3.53], P=0.030). Statistical significance was 
lost after correction for NT-proBNP (HR=1.61 [0.81 – 3.20], P=0.175). In acute HF, higher plasma 
KIM-1 levels were associated with higher creatinine, lower albumin, and presence of diabetes. Log 
plasma KIM-1 predicted 60-day HF rehospitalization (HR=1.27 [1.03-1.55], P=0.024), but not 180-
day mortality or 60-day death or renal or cardiovascular rehospitalization. 
Conclusions 
Plasma KIM-1 is associated with glomerular filtration and urinary NAG, but not with other urinary 
tubular damage markers. Plasma KIM-1 does not predict outcome in chronic HF after correction for 
NT-proBNP. In acute HF, plasma KIM-1 predicts HF rehospitalization in multivariable analysis. 
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Abbreviations 
BMI  Body Mass Index 
BNP  Brain Natriuretic Peptide 
BSA  Body Surface Area 
BUN  Blood Urea Nitrogen 
CRP  C-reactive protein 
ELISA Enzyme-linked immonsorbent assays 
ERPF  Effective Renal Plasma Flow 
FF  Filtration Fraction 
GFR  Glomerular Filtration Rate 
HR  Hazard Ratio 
KIM-1 Kidney Injury Molecule-1 
LVEF  Left Ventricular Ejection Fraction 
NAG  N-acetyl-β-D-glucosaminidase 
NGAL Neutrophil Gelatinase-Associated Lipocalin 
NT-proBNP N Terminal pro Brain Natriuretic Peptide  
NYHA New York Heart Association 
PROTECT Placebo-controlled Randomized study of the selective A(1) adenosine receptor 
antagonist rolofylline for patients hospitalized with acute heart failure and volume Overload 
to assess Treatment Effect on Congestion and renal funcTion  
RBF  Renal Blood Flow 
WRF  Worsening Renal Function 
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Introduction 
In patients with heart failure, renal dysfunction and worsening renal function (WRF) are strong 
predictors of morbidity and mortality.1 In these studies, renal function is routinely established by 
(estimated) glomerular filtration rate (GFR).2,3 In addition, markers of tubular damage are elevated in 
heart failure, are associated with WRF, and provide additional and independent prognostic 
information.4-7 A sensitive tubular marker is Kidney Injury Molecule-1 (KIM-1), a protein of the 
proximal tubule which is undetectable in healthy kidneys, but is thought to be expressed in fibrotic 
areas as a result of tubulo-interstitial damage, inflammation and tubular epithelium changes.8,9 Urinary 
KIM-1 was found superior to other tubular markers in predicting WRF, response to diuretic 
withdrawal and was associated with outcome, even after adjustment for other known risk factors in 
heart failure.4,6,10 
Recently, plasma measurements of KIM-1 have become available which have a higher clinical 
applicability in daily cardiology practice. In patients with both acute and chronic kidney injury, plasma 
KIM-1 predicted progression of renal disease.11 However, no data are available on plasma KIM-1 
measurements in patients with heart failure. Therefore, this study aims to evaluate plasma KIM-1 as a 
tubular and prognostic marker in patients with acute and chronic heart failure. 
 
Methods 
We first studied plasma KIM-1 in a renal mechanistic cohort of chronic heart failure patients to 
investigate its association with urinary tubular markers and with renal hemodynamic measurements, 
such as measured GFR by Iothalamate clearance and renal blood flow. Secondly, we further studied 
the association with plasma creatinine and its prognostic value in a cohort of 2033 patients with acute 
heart failure that were included in the PROTECT (Placebo-controlled Randomized study of the 
selective A(1) adenosine receptor antagonist rolofylline for patients hospitalized with acute heart 
failure and volume Overload to assess Treatment Effect on Congestion and renal funcTion) trial.  
 
Renal mechanistic cohort 
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Patient population 
The renal mechanistic, chronic heart failure cohort has been described in detail previously.6 In brief, 
120 stable outpatients with systolic heart failure were included at the University Medical Centre 
Groningen. The protocol was approved by the local medical ethical committee and all patients 
provided written informed consent. All patients used renin-angiotensin system blockers, and all 
medications had been stable for at least 1 month.  
 
Study design 
Measured GFR, effective renal plasma flow (ERPF) and renal blood flow (RBF) were measured on 
two consecutive days by Iothalamate clearance, which is considered the golden standard for measuring 
glomerular function. 12 By multiplication of the radiolabeled tracer 125I-iothalamate with the ratio of 
the plasma and urinary clearance of 131I-hippuran, this method corrects for incomplete bladder 
emptying and dead space. From the ratio of the GFR and ERPF the filtration fraction (FF) was 
calculated and presented as a percentage. GFR, ERPF and RBF are also presented with correction for 
1.73 m² body surface area. 
Serum laboratory assessments such as creatinine, serum blood urea nitrogen (BUN), serum albumin 
and serum cystatin C were measured in venous blood at baseline. Urinary measurements were 
performed using 24 h urine collection. Levels of urinary tubular markers were determined with ELISA 
for neutrophil gelatinase-associated lipocalin (NGAL), with the substrate p-nitrophenyl N-acetyl-beta-
D-glucosaminide for N-acetyl-β-D-glucosaminidase (NAG) and with antibodies for urinary KIM-1. 
Urinary tubular activity was expressed per gram urinary creatinine. In 99 patients plasma KIM-1 was 
measured (lower limit of detection:2 pg/ml, upper limit:1000 pg/ml) by single molecule counting 
technology with the Erenna® Immunoassay System on a microtiter plate assay format (Singulex Inc, 
Alameda, USA). 
 
Follow-up 
We used a composite endpoint of first occurrence of all-cause death, heart transplantation, myocardial 
infarction or hospitalization for heart failure at three years follow-up.13 
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Acute heart failure cohort 
Patient population and study design 
The PROTECT study was a multicenter, double-blind, placebo-controlled study on the effects of 
rolofylline on symptomatic improvement of acute heart failure patients with mild to moderate renal 
function impairment. The details of the design, results, and conclusions have already been 
published.14,15 A total of 2,033 acute heart failure patients with mild to moderate impaired renal 
function (creatinine clearance between 20 to 80 mL/min with Cockcroft–Gault formula) were included 
and randomized to rolofylline or placebo. The overall results were neutral. The study was approved by 
the ethics committee at each participating center, and written informed consent was obtained from all 
participants.  
The following biomarkers were evaluated at baseline: albumin, BUN, creatinine, glucose, hemoglobin, 
potassium, sodium, total cholesterol, triglycerides, uric acid and white blood cell count were measured 
by ICON Laboratories, Farmingdale, New York. N Terminal pro Brain Natriuretic Peptide (NT-
proBNP) was determined at screening using commercial assays available at study sites. NGAL and C-
reactive protein (CRP) were measured in available frozen plasma samples by Alere Inc., San Diego, 
CA, USA. NGAL was measured using sandwich enzyme-linked immonsorbent assays (ELISA) on a 
microtiter plate; CRP was measured using competitive ELISAs on a Luminex platform. Plasma KIM-
1, and brain natriuretic peptide (BNP) were measured from frozen plasma samples collected only at 
baseline by Singulex Inc, Alameda, USA. Plasma KIM-1 was determined in 1,588 baseline samples  
using Single Molecule Counting as described above. 
 
Follow-up 
Three endpoints that relate to heart failure and renal function were evaluated: all-cause mortality 
within 180 days, heart failure rehospitalization within 60 days, and death or cardiovascular or renal 
rehospitalization within 60 days, as described previously.15.16 
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The endpoints were adjusted for the clinical model created for this cohort, with addition of brain 
natriuretic peptide (BNP). This prognostic model consisting of 8 readily available variables has shown 
to perform similarly compared to a more complex model.17 
 
Statistical analysis 
Descriptive statistics were used to examine the relation of quantiles of plasma KIM-1 to covariates. 
Due to different population sizes and differences in plasma KIM-1 range, plasma KIM-1 was divided 
into tertiles for the chronic HF cohort and into quartiles for the acute HF cohort. Prior to analyses the 
distribution of all variables was checked. Data are presented as mean ± SD when normally distributed, 
as median (interquartile range) for skewed variables and as frequencies (percentage) for categorical 
variables. Baseline characteristics were analyzed using ANOVA for normally distributed 
variables and Kruskal-Wallis for skewed variables. For categorical variables Chi-square was 
used. A linear trend was statistically tested with Cochran-Armitage trend test, Jonckheere-
Terpstra test, and linear regression model for categorical variable, non-normally distributing 
continuous variable, and normally distributing continuous variable over quartiles of plasma 
KIM-1 in the acute heart failure cohort, after checking for non-linear trends. If necessary, 
variables were transformed for further analyses. Correlations of log plasma KIM-1 with 
established markers of tubular and glomerular function were investigated. Predictors of log 
plasma KIM-1 were analyzed using univariable and multivariable regression with the backward 
elimination method after including all variables with p<0.10 in univariable analyses. Cox proportional 
hazard models were constructed for all selected endpoints to evaluate the prognostic predictability of 
plasma KIM-1. The proportional hazard assumption was checked by inspection of “log-log” plots for 
quantiles of plasma KIM-1, and Schoenfeld residual plots. In multivariable models of the chronic heart 
failure cohort, log plasma KIM-1 was subsequently adjusted for age, sex, serum creatinine and BUN. 
In PROTECT, log plasma KIM-1 was adjusted for  the clinical model created for this cohort and BNP 
with respect to the three outcomes.17 A two-tailed p-value <0.05 was considered statistically 
significant. Statistical analyses were performed with SPSS and R: A Language and Environment for 
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Statistical Computing, version 3.0.2 (R Foundation for Statistical Computing, Vienna, Austria). ISBN 
3-900051-07-0, www.r-project.org. 
 
Results 
Renal mechanistic cohort (chronic heart failure) 
Patient characteristics 
Baseline characteristics of the renal mechanistic cohort are summarised in table 1. In brief, mean age 
was 60 years (± 11.9), 81% of the patients were male, 36% had a New York Heart Association 
(NYHA) classification of III or IV and mean Left Ventricular Ejection Fraction (LVEF) was 28.6% (± 
9.6). The median value of plasma KIM-1 was 171.5 (122.8 – 325.7) pg/mL. Higher levels of plasma 
KIM-1 were associated with older age (P = 0.001), higher N Terminal pro Brain Natriuretic Peptide 
(NT-proBNP) levels (P = 0.019), higher urinary NAG levels (P = 0.033) and all indices of renal 
function (all P < 0.001). No association was found between levels of plasma KIM-1 and urinary KIM-
1 and urinary NGAL. The  associations between plasma KIM-1 and tubular markers and GFR are 
presented in figure 1. 
 
Linear regression analysis for plasma KIM-1 
Variables associated with log plasma KIM-1 in univariable linear regression analysis are presented in 
supplementary table 1. In multivariable linear regression higher levels of log plasma KIM-1 were 
associated with older age (Beta = 0.016, P = 0.023), more frequent use of an aldosterone antagonist (β 
= 0.439, P = 0.009), higher log serum BUN levels (β = 0.520, P = 0.040) and higher log urinary NAG 
levels (β = 0.213, P = 0.033), r² for the model = 0.604 (table 2). Log urinary KIM-1 was not 
significantly associated with log plasma KIM-1 levels. 
 
Relationship with clinical outcome 
In total, 38 patients experienced an event, among which were 14 all-cause deaths, 18 hospitalizations 
for heart failure, 5 heart transplantations and 1 myocardial infarction. In figure 2, Kaplan-Meier event-
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free survival curves for tertiles of plasma KIM-1 showed that higher levels of plasma KIM-1 (tertile 3) 
are associated with reduced survival (P = 0.019). Cox regression analysis for the combined endpoint is 
presented in table 4a. Higher log plasma KIM-1 levels were associated with adverse clinical outcome 
outcome (Hazard Ratio (HR) = 2.69 (1.52 – 4.76), P = 0.001), even after adjustment for age, gender, 
and GFR per BSA (HR = 1.94 (1.07 – 3.53), P = 0.030). The statistical significance was however lost 
after correction for NT-proBNP (HR = 1.61 (0.81 – 3.20), P = 0.175). 
 
Acute heart failure cohort 
Patient characteristics 
Baseline characteristics of the study population and associations of plasma KIM-1 with the other 
PROTECT variables are presented in table 3. In brief, mean age was 70.9 years (± 11.2), 66% of the 
patients were male, and mean LVEF was 32.5% (± 13.2). The median value of plasma KIM-1 was 
295.1 (182.2-484.2) pg/mL. Higher plasma KIM-1 levels were, among others, associated with older 
age (P < 0.001), higher systolic blood pressure (P < 0.001), higher Body Mass Index (BMI) (P = 
0.001), higher LVEF (P = 0.004), higher frequency of Heart Failure with preserved Ejection Fraction 
(P = 0.011), higher NT-proBNP levels (P < 0.001), higher CRP levels (P < 0.001), higher plasma 
NGAL levels (P < 0.001) and a history of hypertension (P = 0.001), diabetes (P < 0.001), and 
dyslipidemia (P = 0.001). The incidence of worsening renal function, defined as 0.3 mg/dl increase in 
creatinine at day 4, was not different over baseline quartiles of plasma KIM-1 (P = 0.742).  
 
Linear regression analysis for plasma KIM-1 
The univariable regression analysis for plasma KIM-1 in acute heart failure is presented in 
supplementary table 1. In multivariable regression plasma KIM-1 was associated with presence of 
diabetes (β = 0.188, P < 0.001), lower albumin levels (β = -0.164, P = <0.001), higher BUN levels (β 
= 0.104, P = 0.004), higher creatinine levels (β = 0.088, P = 0.013), higher total cholesterol levels (β = 
0.079, P = 0,004), higher systolic blood pressure (β = 0,07, P = 0.008), higher triglyceride levels (β = 
0.058, P = 0.028), older age (β = 0.057, P = 0.021), and higher CRP levels (β = 0.052, P = 0.034), r² of 
the model = 0.137 (table 2).  
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Relationship with clinical outcome 
Cox regression analysis for the endpoints is presented in table 4b. Log plasma KIM-1 was associated 
with all-cause mortality within 180 days (HR = 1.21 (1.03-1.43), P = 0.020) and heart failure 
rehospitalization within 60 days (HR = 1.29 (1.08-1.55), P = 0.006). Log plasma KIM-1 was an 
independent predictor for heart failure rehospitalization even after adjustment for a previous selected 
model that includes age, history of heart failure hospitalization, peripheral edema, systolic blood 
pressure, sodium, BUN, creatinine, and albumine (HR = 1.26 (1.03-1.54), P = 0.028) and these 8 
variables plus BNP (HR 1.27 (1.03-1.55), P = 0.024).  Supplementary figure 2, Kaplan-Meier event-
free survival curves for quartiles of plasma KIM-1 showed that higher levels of plasma KIM-1 
(quartile 4) are associated with a slightly higher probability of heart failure rehospitalization (P = 
0.066). This is confirmed in supplementary table 2, in which the association of plasma KIM-1 with 
outcome is analyzed for quartiles of plasma KIM-1.  
 
Discussion 
In this study, we investigated the reliability of plasma KIM-1 as a marker of tubular kidney 
dysfunction in patients with chronic and acute heart failure and its associations with adverse clinical 
outcome. Plasma KIM-1 is associated with glomerular function and with urinary NAG, but not with 
urinary tubular damage markers and has a moderate association with clinical outcome.  This study is 
the first to study plasma KIM-1 in heart failure. 
 
Marker position of plasma KIM-1 
Previous studies showed that urinary markers of tubular damage provide additional prognostic 
information independent from glomerular function in patients with heart failure.5-7 In addition, urinary 
KIM-1 appeared to be a suitable marker to assess tubular damage and was the best predictor of 
worsening renal function.4,6 Recently, an assay to assess plasma KIM-1 has become available.  
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Contrary to expectations, our study shows that plasms KIM-1 is only moderately associated with other 
markers of tubular damage, but is strongly associated with glomerular function. We only found a 
moderate association with urinary NAG over tertiles of plasma KIM-1. However, urinary NAG was 
the only marker of tubular damage that was associated with GFR, so therefore the association between 
urinary NAG and plasma KIM-1 might be explained through its association with GFR. Both urinary 
KIM-1 and urinary NGAL had no association with either GFR or plasma KIM-1.  
In a previous study in patients with kidney disease, plasma KIM-1 was strongly associated with renal 
injury and decreasing GFR, and they found an association between plasma KIM-1 and urinary KIM-
1.11 The absence of a correlation between plasma KIM-1 and other renal tubular markers, such as 
urinary NGAL and urinary KIM-1 might have several explanations.  
Plasma KIM-1 is encoded by the HAVCR1 gene.18 This gene is widely expressed in the human body, 
and highest levels are found in the testis and kidney. Circulating plasma KIM-1 might be originating 
from other organs and is possibly not specifically linked to renal (tubular) damage. The previous study 
in patients with kidney disease already showed that plasma KIM-1 levels are detectable in healthy 
volunteers and thus in the absence of renal (tubular) damage.11 Due to the pathologic changes that are 
associated with heart failure, it is conceivable that the lungs or the heart itself sheds KIM-1. 
Furthermore, congestion of the hepatic and portal vessels or impaired perfusion may also produce 
pathologic changes in the liver, spleen and intestines.19 Possible difficulties of the kidney in handling 
plasma KIM-1 could play a role, which could be due to the size of KIM-1 (104 kDa).20 Small-
molecularweight proteins (<40 kDa) are freely filtered by the glomeruli, whereas bigger proteins 
(>100 kDa) are almost completely impeded by the glomerular filtration barrier.21 This further implies 
that plasma KIM-1 probably does not originate from the tubulus. Furthermore, in previous research 
plasma NGAL also demonstrated to be associated with decreasing glomerular function,22 which is in 
line with our findings regarding plasma KIM-1. Plasma KIM-1 might be associated with the severity 
of heart failure and comorbidities, which is reflected by the association of higher levels of plasma 
KIM-1 with higher levels of NT-proBNP, BNP and a remarkable association with characteristics of 
the metabolic syndrome in the acute HF cohort, as expressed by the relationship of higher plasma 
KIM-1 with higher BMI, diabetes, dyslipidemia, and hypertension. 
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Plasma KIM-1 and adverse clinical outcome 
Plasma KIM-1 is moderately associated with adverse clinical outcome. In chronic heart failure, the 
association with outcome was maintained even after correction for GFR, but statistical significance 
was lost after correction for NT-proBNP. In acute heart failure plasma KIM-1 was a significant 
predictor of heart failure rehospitalization in multivariable analysis, but not for other endpoints. When 
plasma KIM-1 was evaluated in quartiles, the association with heart failure rehospitalization was only 
significant for the highest quartile of plasma KIM-1 levels. Plasma KIM-1 showed strong associations 
with severity of heart failure in our study, which could explain why plasma KIM-1 predicted heart 
failure rehospitalization but not other endpoints. 
 
Strengths and limitations of the study 
This is the first study investigating the role of plasma KIM-1 in heart failure. We compared plasma 
KIM-1 with several renal indices, and in particular with measured GFR, measured by Iothalamate 
clearance. This increases the reliability of the data for positioning plasma KIM-1 as a marker in this 
cohort. Furthermore, we investigated plasma KIM-1 in both acute and chronic heart failure.  
However, all analyses are retrosepctive and the renal mechanistic cohort is a relatively small, single 
centre cohort with mainly young male patients, with reasonably preserved GFR. Additionally, 
different assays were used for the measurement of KIM-1 in urine and in plasma. 
 
Conclusion and implications 
Plasma KIM-1 is associated with glomerular filtration and with urinary NAG, but not with urinary 
tubular damage markers. Plasma KIM-1 is only moderately associated with clinical outcome. This 
study implicates that plasma KIM-1 is probably not clinically applicable as a tubular damage marker 
in heart failure patients. 
 
Acknowledgements 
 13 
The PROTECT trial was supported by NovaCardia, a subsidiary of Merck. Alere and Singulex kindly 
provided assays and performed biomarker measurements. 
 
Disclosures 
J.E.E., J.M.tM., Y.M., H.L.H., K.D., and P.v.d.M. have nothing to disclose. A.A.V. has received 
speaker and consultancy fees from Merck and NovaCardia. D.J.V.V. has received Board Membership 
fees from Amgen, Biocontrol, Johnson & Johnson, Novartis, Sorbent and Vifor. C.M.O.C. is a 
consultant to Merck. M.M. has received honoraria and reimbursements from NovaCardia, sponsors of 
the study, and from Merck, that purchased the rights to rolofylline after completion of the PROTECT 
pilot study. P.P. has received honoraria from Merck. J.R.T. has received research funds and consulting 
fees from Merck, the producer of rolofylline for the conduct of this study and has also received 
research funds and consulting fees from Abbott, Amgen, Biogen Idec, Corthera, Cytokinetics, Johnson 
and Johnson/ Scios, Novartis, Relypsa and Solvay for research in related areas. G.C. and B.D. are 
employees of Momentum Research Inc, which was contracted to perform work on the project by 
Merck & Co, Inc. J.G.C. was on the Steering Committee for the study, served on the Advisory Board 
for MSD, and received payments for both. M.M.G. has received institutional research support and 
served on a scientific Advisory Board for Merck. D.M.B. is an employee of Merck. H.C.D was an 
employee of NovaCardia and a consultant to Merck. 
 
 14 
References 
1. Damman K, Valente MA, Voors AA, O'Connor CM, van Veldhuisen DJ, Hillege HL. Renal 
impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-
analysis. Eur Heart J 2014;35:455-469. 
2. Mahmoodi BK, Matsushita K, Woodward M, Blankestijn PJ, Cirillo M, Ohkubo T, Rossing P, 
Sarnak MJ, Stengel B, Yamagishi K, Yamashita K, Zhang L, Coresh J, de Jong PE, Astor BC, Chronic 
Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and 
end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet 
2012;380:1649-1661. 
3. Waheed S, Matsushita K, Sang Y, Hoogeveen R, Ballantyne C, Coresh J, Astor BC. Combined 
association of albuminuria and cystatin C-based estimated GFR with mortality, coronary heart disease, 
and heart failure outcomes: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 
2012;60:207-216. 
4. Damman K, Masson S, Hillege HL, Voors AA, van Veldhuisen DJ, Rossignol P, Proietti G, 
Barbuzzi S, Nicolosi GL, Tavazzi L, Maggioni AP, Latini R. Tubular damage and worsening renal 
function in chronic heart failure. JACC Heart Fail 2013;1:417-424. 
5. Driver TH, Katz R, Ix JH, Magnani JW, Peralta CA, Parikh CR, Fried L, Newman AB, Kritchevsky 
SB, Sarnak MJ, Shlipak MG, Health ABC Study. Urinary kidney injury molecule 1 (KIM-1) and 
interleukin 18 (IL-18) as risk markers for heart failure in older adults: the Health, Aging, and Body 
Composition (Health ABC) Study. Am J Kidney Dis 2014;64:49-56. 
6. Damman K, Van Veldhuisen DJ, Navis G, Vaidya VS, Smilde TD, Westenbrink BD, Bonventre JV, 
Voors AA, Hillege HL. Tubular damage in chronic systolic heart failure is associated with reduced 
survival independent of glomerular filtration rate. Heart 2010;96:1297-1302. 
 15 
7. Damman K, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL. Urinary neutrophil gelatinase 
associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart 
failure. Eur J Heart Fail 2008;10:997-1000. 
8. van Timmeren MM, van den Heuvel MC, Bailly V, Bakker SJ, van Goor H, Stegeman CA. Tubular 
kidney injury molecule-1 (KIM-1) in human renal disease. J Pathol 2007;212:209-217. 
9. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney Injury Molecule-1 (KIM-1): 
a novel biomarker for human renal proximal tubule injury. Kidney Int 2002;62:237-244. 
10. Damman K, Ng Kam Chuen MJ, MacFadyen RJ, Lip GY, Gaze D, Collinson PO, Hillege HL, van 
Oeveren W, Voors AA, van Veldhuisen DJ. Volume status and diuretic therapy in systolic heart 
failure and the detection of early abnormalities in renal and tubular function. J Am Coll Cardiol 
2011;57:2233-2241. 
11. Sabbisetti VS, Waikar SS, Antoine DJ, Smiles A, Wang C, Ravisankar A, Ito K, Sharma S, 
Ramadesikan S, Lee M, Briskin R, De Jager PL, Ngo TT, Radlinski M, Dear JW, Park KB, Betensky 
R, Krolewski AS, Bonventre JV. Blood kidney injury molecule-1 is a biomarker of acute and chronic 
kidney injury and predicts progression to ESRD in type I diabetes. J Am Soc Nephrol 2014;25:2177-
2186. 
12. Donker AJ, van der Hem GK, Sluiter WJ, Beekhuis H. A radioisotope method for simultaneous 
determination of the glomerular filtration rate and the effective renal plasma flow. Neth J Med 
1977;20:97-103. 
13. Smilde TD, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL. Drawbacks and prognostic value 
of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. 
Circulation 2006;114:1572-1580. 
14. Weatherley BD, Cotter G, Dittrich HC, DeLucca P, Mansoor GA, Bloomfield DM, Ponikowski P, 
O'Connor CM, Metra M, Massie BM, PROTECT Steering Committee, Investigators, and 
 16 
Coordinators. Design and rationale of the PROTECT study: a placebo-controlled randomized study of 
the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute 
decompensated heart failure and volume overload to assess treatment effect on congestion and renal 
function. J Card Fail 2010;16:25-35. 
15. Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Weatherley BD, 
Cleland JG, Givertz MM, Voors A, DeLucca P, Mansoor GA, Salerno CM, Bloomfield DM, Dittrich 
HC, PROTECT Investigators and Committees. Rolofylline, an adenosine A1-receptor antagonist, in 
acute heart failure. N Engl J Med 2010;363:1419-1428. 
16. Valente MA, Voors AA, Damman K, Van Veldhuisen DJ, Massie BM, O'Connor CM, Metra M, 
Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, Fiuzat 
M, Dittrich HC, Hillege HL. Diuretic response in acute heart failure: clinical characteristics and 
prognostic significance. Eur Heart J 2014;35:1284-1293. 
17. Cleland JG, Chiswell K, Teerlink JR, Stevens S, Fiuzat M, Givertz MM, Davison BA, Mansoor 
GA, Ponikowski P, Voors AA, Cotter G, Metra M, Massie BM, O'Connor CM. Predictors of 
postdischarge outcomes from information acquired shortly after admission for acute heart failure: a 
report from the Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor 
Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and 
Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) Study. 
Circ Heart Fail 2014;7:76-87. 
18. Feigelstock D, Thompson P, Mattoo P, Zhang Y, Kaplan GG. The human homolog of HAVcr-1 
codes for a hepatitis A virus cellular receptor. J Virol 1998;72:6621-6628. 
19. Robbins and Cotran. Chapter 12: The Heart. In: Kumar V, Abbas A, Fausto N, Aster J, eds. 
Pathologic basis of disease. Eigth edition ed: Saunders, Elsevier; 2010. p. 533-534, 535, 536, 537. 
 17 
20. Bailly V, Zhang Z, Meier W, Cate R, Sanicola M, Bonventre JV. Shedding of kidney injury 
molecule-1, a putative adhesion protein involved in renal regeneration. J Biol Chem 2002;277:39739-
39748. 
21. Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidney disease: a mechanistic 
viewpoint. Kidney Int 2008;74:22-36. 
22. Palazzuoli A, Ruocco G, Beltrami M, Franci B, Pellegrini M, Lucani B, Nuti R, Ronco C. 
Admission plasma neutrophil gelatinase associated lipocalin (NGAL) predicts worsening renal 
function during hospitalization and post discharge outcome in patients with acute heart failure. Acute 
Card Care 2014;16:93-101. 
  
 18 
Figure Legends 
 
Figure 1. Relationship between tubular markers and GFR per BSA and tertiles of plasma KIM-
1 in the renal mechanistic cohort. 
Relationship between tertiles of plasma KIM-1 and a) urinary KIM-1, b) urinary NGAL, c) urinary 
NAG, and d) GFR per BSA. Abbreviations: KIM-1: Kidney Injury Molecule-1, NAG: N-acetyl-β-D-
glucosaminidase, NGAL: Neutrophil Gelatinase-Associated Lipocalin, GFR: glomerular filtration rate, 
BSA: body surface area 
 
Figure 2. Kaplan-Meier survival curve for tertiles of plasma KIM-1 in the renal mechanistic 
cohort. 
Log-rank P = 0.019. Abbreviations: KIM-1: Kidney Injury Molecule-1 
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Table 1. Baseline characteristics and relationship between tertiles of plasma KIM-1 in the renal 
mechanistic cohort 
 Tertile 1 (n=33) Tertile 2 (n=33) 
 
Tertile 3 (n=33) 
 
P-value 
Plasma KIM-1 (pg/ml) 103.1 (72.1 – 
122.9) 
171.5 (149.3 – 
207.7) 
353.9 (318.6 – 
421.9) 
 
Clinical characteristics 
Age (years) 54.4 ± 12.0 61.1 ± 10.7 64.8 ± 11.0 0.001  
Gender, n (% male) 27 (82) 25 (76) 28 (85) 0.634  
BMI (kg/m²) 27.1 ± 3.4 27.9 ± 3.7 27.6 ± 3.4 0.601 
NYHA III/IV, n (%) 12 (36) 10 (30) 14 (42) 0.895  
LVEF (%) 29.2 ± 8.8 29.1 ± 9.8 28.3 ± 9.8 0.902 
Diabetes, n (%) 1 (3) 3 (9) 7 (21) 0.057 
Systolic blood pressure 
(mm Hg) 
120.7 ± 20.8 118.1 ± 18.5 119.6 ± 21.8 0.879  
NT-proBNP (ng/L) 520.0 (284.9–
881.2) 
510.6 (212.0–
1973.0) 
1055.0 (483.1–
2755.0) 
0.019 
Prior medication use 
ACE-inhibitor, n (%) 30 (91) 26 (79) 26 (79) 0.321 
ARB, n (%) 3 (9) 8 (24) 6 (18) 0.259 
Beta-blocker, n (%) 29 (88) 30 (91) 24 (73) 0.099 
Diuretics, n (%) 19 (19) 19 (19) 25 (25) 0.208 
Aldosterone antagonist, n 5 (15) 10 (30) 12 (36) 0.137 
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(%) 
Digoxin, n (%) 0 (0) 0 (0) 2 (6) 0.130 
Renal function 
GFR per BSA 
(mL/min/1.73m²) 
86.4 ± 22.5 76.4 ± 23.9 58.2 ± 24.7 <0.001 
ERPF per BSA 
(mL/min/1.73m²) 
306.0 ± 72.1 276.8 ± 82.2 220.7 ± 81.3 <0.001  
RBF per BSA 
(mL/min/1.73m²) 
528.9 ± 133.5 482.7 ± 151.0 371.0 ± 145.4 <0.001  
Creatinine (µmol/L) 94.0 (88.0-108.5) 104.0 (89.0-
117.5) 
125.0 (96.0-147.0) 0.003  
BUN (mg/dL) 17.6 (14.4-19.9) 19.9 (16.5-28.6) 24.4 (20.4-39.6) <0.001  
Cystatin C (mg/L) 0.74 (0.68–0.79) 0.77 (0,67–0.95) 1.00 (0.86–1.26) <0.001 
Urinary markers 
Urinary KIM-1 (ng/gCr) 277.6 (188.4–
546.5) 
376.1 (229.5–
587.7) 
407.0 (219.6–
740.9) 
0.526  
Urinary NGAL (ug/gCr) 178.4 (53.6–
357.2) 
152.5 (64.0–
359.8) 
195.9 (78.4–351.8) 0.892  
Urinary NAG (U/gCr) 9.2 (5.6–13.2) 6.6 (5.1–14.2 13.6 (8.6–19.7) 0.033  
Urinary creatinine 
(mmol/L) 
6.7 (5.1–9.6) 7.2 (5.4–9.6) 6.1 (4.8 – 8.3) 0.345  
Urinary albumin (mg/L) 6.7 (3.8–10.4) 5.9 (3.1–12.3) 5.7 (3.4–26.3) 0.895 
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Abbreviations: ARB: angiotensin II receptor blocker BMI: body mass index, BSA: body surface area, 
BUN: blood urea nitrogen, ERPF: effective renal plasma flow, FF: filtration fraction, GFR: glomerular 
filtration rate, KIM-1: kidney injury molecule-1, LVEF: left ventricular ejection fraction, NAG:  N-
acetyl-β-D-glucosaminidase, NGAL: Neutrophil Gelatinase-Associated Lipocalin, NT-proBNP: N 
Terminal pro Brain Natriuretic Peptide, NYHA: New York Heart Association, RBF: renal blood flow 
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Table 2. Multivariable linear regression for plasma KIM-1 in the renal mechanistic cohort and 
acute heart failure cohort 
Variables Standardized Beta T-value P-value 
Renal mechanistic cohort 
Log BUN 0.337 2.096 0.040 
Aldosterone antagonist 0.302 2.696 0.009 
Age 0.275 2.337 0.023 
GFR per BSA 0.267 1.539 0.129 
Log urinary NAG 0.245 2.175 0.033 
Beta blocker -0.131 -1.266 0.210 
Gender 0.107 0.986 0.328 
Log urinary KIM-1 0.092 0.846 0.401 
Log NT-proBNP 0.042 0.350 0.727 
Acute heart failure cohort 
Diabetes 0.188 7.529 <0.001 
Albumin -0.164 -6.431 <0.001 
Log BUN 0.104 2.847 0.004 
Log Creatinine 0.088 2.479 0.013 
Total Cholesterol 0.079 2.862 0.004 
Systolic blood pressure 0.07 2.674 0.008 
Triglycerides 0.058 2.196 0.028 
Age 0.057 2.314 0.021 
CRP 0.052 2.116 0.034 
 
Abbreviations: BMI: body mass index, BUN: blood urea nitrogen, CRP: C-reactive protein, GFR: 
glomerular filtration rate, KIM-1: kidney injury molecule-1, NAG: N-acetyl-β-D-glucosaminidase, 
NT-proBNP: N terminal pro brain natriuretic peptide 
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Table 3. Baseline characteristics and relationship between quartiles of plasma KIM-1 in acute 
heart failure 
  Q1 Q2 Q3 Q4 P-value  
for trend  (n=397) (n=397) (n=397) (n=397) 
KIM-1 value (pg/ml) 
(median, [min-max]) 
133.96  
[2.00, 182.18] 
231.33 
 [182.19, 
295.05] 
371.73  
[295.15, 
483.60] 
735.32 
 [485.86, 
1000.00] 
Age (years) 68.65 ±12.72 71.69 ±11.14 71.67 ±10.09 71.46 ±10.32 <0.001 
Male gender (%) 272 (68.5)  272 (68.5)  250 (63.0)  254 (64.0)  0.718  
Systolic blood 
pressure (mmHg) 
122.61 ±16.86 122.93 ±17.28 124.32 ±16.98 129.10 ±17.92 <0.001 
BMI (kg/m²) 27.93 ±6.17 28.45 ±5.70 29.05 ±6.04 29.57 ±5.89 <0.001 
Rolofylline 
administration (%) 
260 (65.5)  265 (66.8)  265 (66.8)  272 (68.5)  0.391  
LVEF (%) 30.2 ±12.4 31.4 ±12.5 34.4 ±13.9 34.0 ±13.6 <0.001 
HFpEF (LVEF≥45) 
(%) 
27 (14.7) 35 (17.9) 42 (22.7) 48 (24.1) 0.011 
WRF (%) 69 (18.2) 71 (18.4) 69 (18) 71 (19.3) 0.742 
Prior medication use 
ACEI (%) 250 (63.1)  268 (67.5)  238 (59.9)  236 (59.4)  0.087  
ARB (%) 54 (13.6)  57 (14.4)  67 (16.9)  63 (15.9)  0.253  
Beta blocker (%) 298 (75.3)  290 (73.0)  304 (76.6)  303 (76.3)  0.486  
Calcium channel 
blocker (%) 
51 (12.9)  46 (11.6)  48 (12.1)  80 (20.2)  0.004  
Aldosterone inhibitor 
(%) 
200 (50.5)  202 (50.9)  165 (41.6)  149 (37.5)  <0.001 
Digoxin (%) 123 (31.1)  126 (31.7)  108 ( 27.2)  100 (25.2)  0.029  
Medical history           
Hypertension (%) 293 (73.8)  322 (81.1)  319 (80.4)  337 (84.9)  <0.001 
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Diabetes (%) 109 (27.5)  151 (38.0)  202 (50.9)  271 (68.3)  <0.001 
Dyslipidemia (%) 197 (49.6)  174 (43.9)  203 (51.1)  233 (58.7)  0.002  
Biomarkers 
Albumin (g/dL) 4 (3.7-4.3) 3.9 (3.6-4.1) 3.8 (3.5-4.1) 3.7 (3.5-4) <0.001 
BNP (pg/mL) 357.7 (219.4-
664) 
474.1 (282.3-
798.9) 
489.8 (274.8-
850.4) 
463.6 (255-
861.6) 
0.003 
BUN (mg/dl) 24 (18-32) 30 (22-41) 32 (24-44) 34.5 (25-48) <0.001 
NT-proBNP (pg/mL) 3000 (496.0-
62810.0) 
3000 (1249.0-
154312.0) 
3000 (1388.0-
63501.0) 
3000 (646.2-
48778.0) 
<0.001 
Total cholesterol 
(mg/dl) 
144.5 (116-
169.2) 
139 (118-168) 136 (155-
168.8) 
144 (119.2-
184) 
0.035 
Creatinine (mg/dl) 1.2 (1-1.5) 1.4 (1.1-1.7) 1.4 (1.2-1.8) 1.6 (1.2-2) <0.001 
CRP (ng/mL) 10787.5 
(5751.1-
23260.7) 
13289 
(7458.5-
26374.6) 
15434.9 
(8064-
29171.1) 
16377.1 
(8305.6-
32659.8) 
<0.001 
Glucose (mg/dL) 124 (103-154) 124 (101-159) 126 (103-164) 136 (106-185) <0.001 
Hemoglobin (g/dL) 12.9 (11.6-
14.2) 
12.6 (11.4-
13.9) 
12.4 (11.2-
13.7) 
12 (10.9-13.4) <0.001 
NGAL (ng/mL) 63.2 (42.4-
95.5) 
77.7 (52-
119.4) 
89.8 (56.5-
145.5) 
108.7 (71-
180.7) 
<0.001 
Potassium (mmol/L) 4.2 (3.8-4.6) 4.3 (3.9-4.6) 4.2 (3.8-4.6) 4.2 (3.9-4.7) 0.096 
Triglycerides 
(mmol/L) 
84 (63-112) 82 (60-110) 87 (65-119) 101 (72-142) <0.001 
Uric acid (mg/dL) 8.3 (6.8-10.2) 8.8 (7.2-10.6) 9.4 (7.6-10.8) 8.7 (7.2-10.4) 0.064 
 
Abbreviations: ACEI: ACE-inhibitor, ARB: angiotensin II receptor blocker, BMI: body mass index, 
BNP: brain natriuretic peptide, BUN: blood urea nitrogen, CRP: C-reactive protein, HFpEF: heart 
failure with preserved ejection fraction, KIM-1: kidney injury molecule-1, LVEF: left ventricular 
ejection fraction, NGAL: Neutrophil Gelatinase-Associated Lipocalin, NT-proBNP: N terminal pro 
brain natriuretic peptide, WRF: worsening renal function 
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Table 4a. Cox Regression analysis for the combined endpoint in the renal mechanistic cohort 
Variable Hazard ratio (95% CI) P-value 
Per log plasma KIM-1 2.69 (1.52 – 4.76) 0.001 
- Adjusted for age and gender 2.69 (1.51 – 4.81) 0.001 
- Adjusted for above and GFR per BSA 1.94 (1.07 – 3.53) 0.030 
- Adjusted for above and log NT-proBNP 1.61 (0.81 – 3.20) 0.175 
- Adjusted for above and log BUN 1.61 (0.81 – 3.23) 0.178 
 
Abbreviations: BSA: body surface area, BUN: blood urea nitrogen, CI: confidence interval, GFR: 
glomerular filtration rate, HR: Hazard Ratio, KIM-1: kidney injury molecule-1, NT-proBNP: N 
terminal pro brain natriuretic peptide 
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Table 4b. Cox regression analysis for 3 outcomes in acute heart failure 
Outcomes Univariable Cox Adjusted for age, 
previous heart failure 
hospitalization, 
peripheral edema, SBP, 
sodium, urea, 
creatinine and albumin 
Adjusted for the 
previous model + BNP 
 HR per log 
plasma 
KIM-1 
(95% CI) 
P-value HR per log 
plasma 
KIM-1 
(95% CI) 
P-value HR per log 
plasma 
KIM-1 
(95% CI) 
P-value 
Death within 180 days 1.21 (1.03-
1.43) 
0.020 1.03 (0.89-
1.21) 
0.699   
Heart failure 
Rehospitalization within 
60 days 
1.29 (1.08-
1.55) 
0.006 1.26 (1.03-
1.54) 
0.028 1.27 (1.03-
1.55) 
0.024 
Death or Cardiovascular 
or Renal Rehospitalization 
within 60 days 
1.05 (0.93-
1.19) 
0.396     
 
Abbreviations: BNP: brain natriuretic peptide, CI: confidence interval, HR: Hazard Ratio, SBP: 
systolic blood pressure 
  
 
  
 
